B2i Digital is pleased to highlight five innovators making an impact:
Unicycive Therapeutics is advancing new kidney disease treatments; CareCloud is transforming healthcare technology; Top Ships is a leader in global shipping; Treasure Global is driving financial tech innovation; and AIM Immunotech is pioneering immuno-therapies.
These boundary-pushing B2i Digital Featured Companies are driving change across biotech, healthcare, logistics, and fintech. Read on for their latest developments.
Recent News: Unicycive
Unicycive Announces Positive Results for Lead Drug Candidate OLC as Alternative Hyperphosphatemia Treatment
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a clinical-stage biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug candidate is oxylanthanum carbonate (OLC), an investigational phosphate binding agent for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The company is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. Two clinical studies were conducted on over 100 healthy volunteers as part of the clinical development program. Based on the results from studies announced on July 18, 2023, pharmacodynamic bioequivalence of OLC to the drug Fosrenol was established. This is an important milestone for Unicycive, as it shows that OLC may be an effective alternative treatment option requiring a lower pill burden than current hyperphosphatemia drugs, potentially improving patient adherence.
CareCloud Partners with Google Cloud to Bring Generative AI to Smaller Clinics
CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO) is a leader in healthcare technology solutions for medical practices and health systems. CareCloud announced a collaboration with Google Cloud on July 27, 2023, to use generative AI to transform and enhance the operational efficiency and capabilities of ambulatory practices, bringing advanced technology to small and medium healthcare providers. By leveraging Google Cloud's Vertex AI and Generative AI App Builder, CareCloud aims to provide timely data access and improved services. The first CareCloud solution with generative AI is expected to be available within months. This partnership is significant as it may extend the benefits of cutting-edge generative AI technology to smaller clinics and doctor's offices that typically lack the resources of large hospital systems, improving healthcare services and accessibility.
Top Ships Announces $72 Million in Additional Revenue from Charter Extensions
Top Ships, Inc. (Nasdaq: TOPS) is an international tanker vessel owner and operator. On July 20, 2023, Top Ships announced it extended time charter agreements for two of its Suezmax vessels for up to 36 months after their current charters expire in 2024. The extensions are expected to generate an additional $72 million in revenue. This is a potentially significant development for Top Ships as it provides improved revenue visibility and extends charter coverage through 2027 amid strong prevailing tanker market rates.
Treasure Global CEO Boosts Holdings and Forges Government Partnership, Showcasing Company's Potential
Treasure Global Inc (Nasdaq: TGL) is a Malaysian technology solutions provider. On July 28, 2023, Treasure Global announced its CEO Sam Teo purchased 121,802 additional shares valued at $101,096, increasing his stake in the company. Teo cited his belief in Treasure Global's potential and value. Previously on July 25, Treasure Global announced a collaboration with Malaysia's Ministry of Domestic Trade and Cost of Living to launch the 'Payung Rahmah' initiative, which provides discounted e-vouchers on necessities through Treasure Global's ZCITY app. The collaboration aims to assist low-income Malaysians and is anticipated to grow ZCITY's user base. Together, the developments showcase Treasure Global's innovation, strategic partnerships, and future outlook.
AIM Immunotech Doses First Patient in Phase 2 Trial of Ampligen for Post-COVID Conditions
AIM Immunotech, Inc. (NYSE American: AIM) is a clinical-stage immuno-pharma company. On July 10, 2023, AIM announced it has enrolled and dosed the first subject in a Phase 2 study evaluating its drug candidate Ampligen as a potential treatment for post-COVID conditions. The study is expected to enroll approximately 80 subjects across 10 U.S. sites, with completion targeted for Q4 2023. This marks a potentially important milestone for AIM as it evaluates Ampligen's potential to address the growing public health crisis of long COVID. There are currently no FDA-approved treatments for post-COVID conditions.
B2i Digital, Inc. provides digital marketing support to the above mentioned Featured Companies, the Featured Companies hosted on b2idigital.com and the Featured Conference companies hosted on b2idigital.com. B2i Digital has not independently verified the accuracy of the information contained herein or on b2idigital.com. B2I Digital, Inc. makes no warranties as to the accuracy of any information provided. No content contained herein or on b2idigital.com shall be considered an offer to solicit the sale of any security. Please reference full disclaimer at https://b2idigital.com/disclaimer.
We trust that you will find these timely updates on our Feature Companies to be of value. Explore their complete profiles to gain a deeper understanding of their journey and discover more about the 17 exceptional Featured Companies we showcase.
Furthermore, we have profiled an impressive compilation of almost 500 exceptional companies that have been featured at conferences hosted by Maxim Group, Roth MKM, and other prominent organizations we have supported. This comprehensive list of Featured Conferences is sure to pique your interest. If you would like to be introduced to any of these companies' management teams, please don't hesitate to reach out to us.
Also, stay tuned for our full fall schedule of conferences hosted by The Benchmark Company, Roth MKM and Maxim Group.
Wishing you a fantastic week ahead and feel free to reach out anytime.
David Shapiro Chief Executive Officer B2i Digital, Inc. 212-579-4844 (office) 917-806-4171 (cell)
